MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, n patients with refractory HR+/HER2- metastatic breast cancer
- Dickler, M.N.
- Tolaney, S.M.
- Rugo, H.S.
- Cortes, J.
- Dieras, V.
- Patt, D.
- Wildiers, H.
- Hudis, C.A.
- O'Shaughnessy, J.
- Zamora, E.
- Yardley, D.A.
- Frenzel, M.
- Koustenis, A.
- Baselga, J.
ISSN: 1557-3265, 1078-0432
Année de publication: 2017
Volumen: 23
Número: 17
Pages: 5218-5224
Type: Article